HEMGENIX - AN OVERVIEW

Variety of qualified sufferers: CDEC talked about the uncertainty in the volume of clients with reasonably significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some clients that are categorized as possessing mild or reasonable ailment could have a serious blee